The patient perspective on the new EU HTA Regulation

CDDF webinar, 28 September

Julie Spony, EPF Policy Officer





The importance of HTA for patients

Patients are the ultimate users of health technologies

 Decisions taken on the availability and reimbursement of technologies have an impact on access to quality healthcare

3. HTA can prevent the funding of **technologies** with limited or no added value







Patient involvement in HTA

Nothing about us without us



Democratisation of the decision-making process



 Experiential knowledge of living with a chronic or lifelong condition



 Contribution to robust evidence to support informed decisionmaking





Patient involvement in HTA at national level

- 27 different processes leading to disparities
- Uneven involvement of patients

Health **Technology** Assessment (HTA)













Patient involvement in HTA at EU level



2006-2023: European
 Network for Health and
 Technology (EUnetHTA) and
 the Stakeholder Forum

• 2021: **EU HTA Regulation**with mandatory patient
involvement





The HTA Regulation & patient involvement





- Patient experts in:
 - Joint Clinical Assessment
 - Joint Scientific Consultation
- Patient representatives in the HTA Stakeholder Network

But who, what, when, where and how?



EUnetHTA 21 deliverable & patient involvement

Stage	Individual patients	Patient organisations
Joint Scientific Consultation	Input	
Scoping	Input	Input
Joint Clinical Assessment	Input	Input
Appraisal process at national level	If relevant in national legislation	If relevant in national legislation
Emerging technologies		Through the Stakeholder Network and for those outside, only if requested by the Coordination Group
Annual Work Programme		Through the Stakeholder Network







Involvement of patient expert


Challenges

- Lack of profiles
- Lack of clarity on conflict of interest criteria
- Unavailability of relevant profiles
- Timely involvement

Enablers

- Clarifying the concept of expert patient
- Anticipate the search for relevant expert patients
- Constructive interpretation of conflict of interest criteria (as is done at the EMA)
- Involve POs constructively in identifying potential profiles.







Involvement of patient organisations

Challenges

- Lack of clarity on conflict of interest criteria
- No mention of financial support for POs
- The role of national POs still needs to be clarified



Enablers

- Predictability of PO involvement
- Clearly define conflict of interest criteria
- Clarify the governance framework to represent the voice of national POs
- Recognise the capacities required by POs







What is EPF doing to prepare the patient community?

EPF European Patients Forum

- Advocacy activities
- Representatives in the EU HTA Stakeholder Network



 European Capacity Building for Patients (EUCAPA) project





THANK YOU FOR YOUR ATTENTION

Follow us on Social Media!

- f /europeanpatientsforum
- /eupatientsforum
- /eupatient
- in linkedin.com/company/european-patients-forum/
- anchor.fm/eupatients

info@eu-patient.eu www.eu-patient.eu

